The present invention relates to selectively targeting tumoral vasculature invivo using a human recombinant scFv, L19, to the angiogenesis marker ED-Bdomain of fibronectin. In preferred embodiments, a complete human IgG1 isemployed having the variable regions of L19. In other embodiments is employeda mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4domain of a secretory IgE isoform that naturally contains a cysteine in itsCOOH terminal and which forms a covalently linked dimer. Different in vivobehaviour of the antibody formats is exploitable for different diagnosticand/or therapeutic purposes, depending on clinical needs and disease. Theantibody molecules may be labelled as described.
